Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Head & Neck 2Thoracic 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Pancreatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Hypoxia 2Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × TH 302 × Genitourinary × Clear all
NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

Phase 1/2 Recruiting
71 enrolled
GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡